T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$2.31B |
| 2 |
Apple
AAPL
|
+$1.58B |
| 3 |
Sherwin-Williams
SHW
|
+$1.37B |
| 4 |
HubSpot
HUBS
|
+$1.32B |
| 5 |
Kenvue
KVUE
|
+$1.25B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.37B |
| 2 |
Lam Research
LRCX
|
+$1.54B |
| 3 |
Applied Materials
AMAT
|
+$1.33B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$1.19B |
| 5 |
Halliburton
HAL
|
+$1.16B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.32% |
| 2 | Healthcare | 15.15% |
| 3 | Financials | 10.54% |
| 4 | Consumer Discretionary | 10.48% |
| 5 | Communication Services | 8.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
851
Monte Rosa Therapeutics
GLUE
$1.35B
| $35M | ﹤0.01% |
6,601,141
+623,554
| +10% | +$3.15M |
|
852
BrightSpring Health Services
BTSG
$11.9B
| $34.8M | ﹤0.01% |
2,369,652
+857,471
| +57% | +$10.7M |
|
853
First Industrial Realty Trust
FR
$8.4B
| $34.7M | ﹤0.01% |
619,519
+13,085
| +2% | +$705K |
|
854
Inspire Medical Systems
INSP
$1.68B
| $34.6M | ﹤0.01% |
164,105
-200,766
| -55% | -$34.9M |
|
855
LyondellBasell Industries
LYB
$20.2B
| $34.5M | ﹤0.01% |
359,527
+2,574
| +0.7% | +$247K |
|
856
Immunovant
IMVT
$8.64B
| $34.5M | ﹤0.01% |
1,209,046
-152,603
| -11% | -$4.5M |
|
857
Advanced Energy
AEIS
$13.2B
| $34.4M | ﹤0.01% |
327,267
-6,505
| -2% | -$683K |
|
858
Ollie's Bargain Outlet
OLLI
$4.7B
| $34.3M | ﹤0.01% |
353,170
+190,483
| +117% | +$18.4M |
|
859
EPAM Systems
EPAM
$5.24B
| $34.3M | ﹤0.01% |
172,277
+69,340
| +67% | +$13.9M |
|
860
Charles River Laboratories
CRL
$13.4B
| $34.1M | ﹤0.01% |
172,906
-468,079
| -73% | -$97.3M |
|
|
CTRA
861
DELISTED
Coterra Energy
CTRA
| $33.7M | ﹤0.01% |
1,409,074
-12,434
| -0.9% | -$307K |
|
|
EFOR
862
Everforth Inc
EFOR
$1.37B
| $33.7M | ﹤0.01% |
361,307
+75,431
| +26% | +$7M |
|
863
Brown-Forman Class B
BF.B
$12.9B
| $33.5M | ﹤0.01% |
681,332
+61,796
| +10% | +$2.78M |
|
864
Eversource Energy
ES
$27.2B
| $33.3M | ﹤0.01% |
489,258
+2,940
| +0.6% | +$190K |
|
865
Akamai
AKAM
$18B
| $33.2M | ﹤0.01% |
329,121
+120,104
| +57% | +$11.7M |
|
866
T. Rowe Price
TROW
$23.7B
| $32.9M | ﹤0.01% |
302,016
-3,853
| -1% | -$423K |
|
867
Pebblebrook Hotel Trust
PEB
$2.05B
| $32.8M | ﹤0.01% |
2,475,360
-364,720
| -13% | -$4.79M |
|
868
Prestige Consumer Healthcare
PBH
$2.43B
| $32.7M | ﹤0.01% |
453,406
+7,496
| +2% | +$531K |
|
869
Box
BOX
$4.66B
| $32.3M | ﹤0.01% |
987,214
-21,028
| -2% | -$614K |
|
870
Landstar System
LSTR
$6.4B
| $32.3M | ﹤0.01% |
170,906
+5,998
| +4% | +$1.11M |
|
871
Braze
BRZE
$3.36B
| $32.2M | ﹤0.01% |
994,258
+208,008
| +26% | +$8.21M |
|
872
Geron
GERN
$982M
| $31.9M | ﹤0.01% |
7,036,618
-4,241,305
| -38% | -$19.3M |
|
873
Qualys
QLYS
$6.78B
| $31.5M | ﹤0.01% |
245,404
-46,237
| -16% | -$6.1M |
|
|
K
874
DELISTED
Kellanova
K
| $31.5M | ﹤0.01% |
390,538
+25,146
| +7% | +$1.79M |
|
|
BOW
875
Bowhead Specialty Holdings
BOW
$1.1B
| $31.4M | ﹤0.01% |
1,120,333
-2,240
| -0.2% | -$62.8K |
|
Similar funds
T. Rowe Price Associates's Q3 2024 Portfolio in Review
As of Q3 2024, T. Rowe Price Associates held 3,059 positions worth $869B, up 3.9% from $836B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Trading was light in Q3 2024: portfolio turnover was 4.3%. T. Rowe Price Associates opened 82 new positions and exited 51, leaving the 3,059-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 34% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q3 2024 buy was Lineage Inc: 4,699,854 shares worth $368M.
- T. Rowe Price Associates added most to Advanced Micro Devices in Q3 2024, an estimated $2.31B increase.
- T. Rowe Price Associates's biggest Q3 2024 reduction was NVIDIA, cutting an estimated $4.37B.
- T. Rowe Price Associates fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $75.2M.
- T. Rowe Price Associates's ten largest holdings make up 34% of its $869B portfolio in Q3 2024.
- T. Rowe Price Associates opened 82 new positions and closed 51 in Q3 2024.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $869B.
Based on T. Rowe Price Associates's 13F filing for Q3 2024, filed 14 Nov 2024.